| DB ID | MyCo_1570 |
| Title | Applying host disease status biomarkers to therapeutic response monitoring in invasive aspergillosis patients |
| Year | 2019 |
| PMID | 29370415 |
| Fungal Diseases involved | Invasive aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | This study was approved by Rutgers Health Sciences Institutional Review Board. |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | CRP |
| Biomarker Full Name | C-reactive protein |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | USA |
| Cohort | A total of 81 serum samples from 15 patients treated at the University of Florida banked in the AsTeC repository were included in this study. |
| Cohort No. | 15 |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive aspergillosis (IA) is a devastating disease of im-munocompromised patients with mortality ranging from 50% to 90%. One critical factor impeding successful management of IA is the lack of suitable tools to assess dis- ease progression and treatment response, particularly early during the course of therapy. In the absence of reliable and effective therapeutic biomarkers, currently a combi- nation of clinical, radiological, and mycological parame- ters are used for assessment of clinical response. How- ever, these parameters are imprecise and lack suitable sen- sitivity to observe clinical changes during the first 2 weeks of antifungal therapy. Indeed, pulmonary infiltrates often worsen during the first 1–2 weeks in patients who ulti- mately are scored as responders. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | Human haptoglobin ELISA kit (GenWay Biotech Inc., San Diego, CA, USA), a human CRP ELISA kit (GenWay), and a human ANXA1 ELISA kit (Cloud-Clone Corp., Katy, TX, USA) |
| Assay Data | None |
| Validation Techniques used | ELISA |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
